Background Previous large chemoprevention studies have not recruited significant numbers of minorities. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a large phase III study evaluating the impact of selenium and vitamin E on the clinical incidence of prostate cancer. Over 400 SELECT study sites in the USA, Canada, and Puerto Rico recruited men to this trial. The SELECT recruitment goal was 24% minorities, with 20% black, 3% Hispanic, and 1% Asian participants. The goal for black participants was set at 20% because of their proportion in the United States population and their prevalence of prostate cancer.
Methods The minority recruitment strategies in SELECT were to: 1) consider minority recruitment during site selection; 2) expand the eligibility criteria by lowering the age criterion for black men and including men with controlled co-morbid illnesses; 3) develop a national infrastructure; 4) give additional funds to sites with the potential to increase black enrollment; and 5) provide resources to maximize free media opportunities to promote SELECT.
Results SELECT recruitment began in August 2001 and was intended to last five years, but concluded two years ahead of schedule in June 2004. Of the 35 534 participants enrolled, 21% were minorities, with 15% black, 5% Hispanic, and 1% Asian.
Conclusions Careful planning, recruitment of large numbers of clinical centers and adequate resources accomplished by the combined efforts of the National Cancer Institute (NCI), Southwest Oncology Group (SWOG), SELECT Recruitment and Adherence Committee (RAC), SELECT Minority and Medically Underserved Subcommittee (MMUS), and the local SELECT sites resulted in attainment of the estimated sample size ahead of schedule and recruitment of the largest percentage of black participants ever randomized to a cancer prevention trial.
Get full access to this article
View all access options for this article.
References
1.
1. Department of Health and Human Services.Healthy People 2000: National health promotion and disease prevention objectives. Sudbury, MA: Public Health Service (PHS), 1991.
2.
2. Department of Health and Human Services.Healthy People 2010. Understanding and improving health; objectives for improving health. Washington, DC: U.S. Government Printing Office, November 2000.
3.
3. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin2005; 55: 10–30.
4.
4. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA2002; 287: 2106–2113.
5.
5. Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol2003; 169: 245–250.
6.
6. Smedley BD, Stith AY, Nelson AR (eds). Unequal treatment confronting racial and ethnic disparities in health care. Institute of Medicine of the National Academies, Washington, DC: National Academic Press, 2003: 5–6.
8. Tangrea JA. Patient participation and compliance in cancer chemoprevention trials: issues and concerns. Proc Soc Exp Biol Med1997216-260.
9.
9. Monpour CM, Atkinson JO, Thomas SM et al.Minority recruitment in the prostate cancer prevention trial. Ann Epidemiol2000; 10: S85–S91.
10.
10. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA2004;291: 2720-2726.
11.
11. Lovato LC, Hill K, Hertert S, Hunninghake DB, Probstfield JL. Recruitment for controlled clinical trials: literature summary and annotated bibliography. Control Clin Trials1997; 18: 328–357.
12.
12. Gorelick PB, Harris Y, Burnett B, Bonecutter FJ.The recruitment triangle: reasons why African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial. An interim report from the African-American Antiplatelet Stroke Prevention Study (AAASPS). J Natl Med Assoc1998; 90: 141–145.
13.
13. Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst1995; 87: 1747–1759.
14.
14. Giuliano AR, Mokuau N, Hughes C et al.Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors. Ann Epidemiol2000; 10: S22–S34.
15.
15. Woods VD, Montgomery SB, Herring RP.Recruiting black/African American men for research on prostate cancer prevention. Cancer2004; 100: 1017–1025.
16.
16. Powell IJ, Gelfand DE, Parzuchowski J, Heilburn L, Franklin A. A successful recruitment process of African American men for early detection of prostate cancer. Cancer1995; 75: 1880–1884.
17.
17. Gotay CC. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med1991; 33: 569–577.
18.
18. McCaskill-Stevens W, Pinto H, Marcus AC et al.Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. J Clin Oncol1999; 17: 1029–1039.
19.
19. Pinto HA, McCaskill-Stevens W, Wolfe P, Marcus AC. Physician perspectives on increasing minorities in cancer clinical trials: an Eastern Cooperative Oncology Group (ECOG) Initiative. Ann Epidemiol2000; 10: S78–S84.
20.
20. Fouad MH, Partridge E, Green BL et al. Minority recruitment in clinical trials: a conference at Tuskegee, researchers and the community. Ann Epidemiol2000; 10: S35–S40.
21.
21. Harris Y, Gorelick PB, Samuels P, Bempong I.Why African Americans may not be participating in clinical trials. J Natl Med Assoc1996; 88: 630–634.
22.
22. Millon-Underwood S, Sanders E, Davis M.Determinants of participation in state-of-the-art cancer prevention, early detection screening, and treatment trials among African-Americans. Cancer Nurs1993; 16: 25–33.
23.
23. Green BL, Partridge EE, Fouad MN, Kohler C, Crayton EF, Alexander L. African-American attitudes regarding cancer clinical trials and research studies: results from focus group methodology. Ethn Dis2000; 10: 76–86.
24.
24. Probstfield JL, Wittes JT, Hunninghake DB.Recruitment in NHLBI population-based studies and clinical trials: data analysis and survey results. Control Clin Trials1987; 8: 141S–149S.
25.
25. Paskett ED, DeGraffinreid CR, Tatum CM, Margitic SE. The recruitment of African-Americans to cancer prevention and control studies. Prev Med1996; 25547-553.
26.
26. Probstfield JL. The clinical trial prerandomization compliance (adherence) screen. In Cramer JA, Spilker B eds. Patient compliance in medical practice and clinical trials: New York, Raven Press: 1991: 323–334.
27.
27. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. Published as a separate Part VIII in the Federal Register of 28 March 1994, Bethesda, MD, 59 FR: 14508–13.
28.
28. National Institutes of Health Revitalization Act, Public Law 1993, Washington, DC, 103–43.
29.
29. Klein EA, Thompson IM, Lippman SM et al. The selenium and vitamin E cancer prevention trial. World J Urol2003; 21: 21–27.
30.
30. Klein EA, Thompson IM, Lippman SM et al. SELECT: the selenium and vitamin E cancer prevention trial: rationale and design. Prostate Cancer Prostatic Dis2000; 3: 145–151.
31.
31. Department of Health and Human Sciences, Centres for Disease Control and Prevention.The National Center for HIV, STD, and TB Prevention, The Tuskegee Timeline. Available at http://www.cdc.gov/nchstp/od/tuskegee/time.htm (access date 7 April 2005).
32.
32. Canadian Statistics. Visible minority Population, by Age Group (2001 Census). Available at http://www40.statcan.ca/l01/cst01/demo50a.htm (access date 6 June 2005).
33.
33. Profile of General Demographic Characteristics: 2000. Census 2000 Summary File 1 (SF 1) 100-Percent Data. Geographic Area: Puerto Rico. Available at http://factfinder.census.gov/servlet/QTTable?_bmy&geo_id04000US72&-qr_nameDEC_2000_SF1_U_DP1&-ds_nameDEC_2000_SF1_U (access date 6 June 2005).
34.
34. Profile of General Demographic Characteristics: 2000. Census 2000 Summary File 1 (SF 1) 100-Percent Data. Geographic Area: United States. Available at http://factfinder.census.gov/servlet/QTTable?_bmy&-geo_id01000US&-qr_nameDEC_2000_SF1_U_DP1&-ds_nameDEC_2000_SF1_U&-redoLogfalse (access date 6 June 2005).
35.
35. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med2003349215-224.
